Medicine goes to school: teachers as sickness brokers for ADHD by Phillips, Christine
PLoS Medicine  |  www.plosmedicine.org 0433
 Essay 
April 2006  |  Volume 3  |  Issue 4  |  e182
 Over the last twenty years, attention deﬁ cit hyperactivity disorder (ADHD) has 
emerged as a disorder of importance 
in childhood. Prescription of 
psychostimulants for ADHD escalated 
in many countries through the 1990s. 
Between 1990 and 1995, prescriptions 
of methylphenidate for young people 
increased 2.5-fold in the US [1], and 
5-fold in Canada [2]. In New South 
Wales, Australia, rates of treatment for 
children in 2000 were nine times those 
in 1990 [3]. 
 ADHD joins dyslexia and glue 
ear as disorders that are considered 
signiﬁ cant primarily because of their 
effects on educational performance. 
Medicalising educational performance 
can help children receive specialised 
medical and educational services; at the 
same time it can lead to them receiving 
medications or surgical therapies which 
may have short-term and long-term ill 
effects. 
 In the case of ADHD, there has 
been a complex, often heated debate 
in the public domain about the 
verity of the illness and the personal 
cost-beneﬁ t ratio of treatment with 
psychostimulant medication [4–6]. 
Much of the polemic for and against 
psychostimulants is concerned with the 
part played by doctors, the prescribers 
of medication, in diagnosing or 
discounting ADHD. ADHD is, however, 
a disorder of educational performance, 
and so teachers have a critical role 
in advocating for the illness, and its 
medical treatment. This essay explores 
the roles of teachers as 
brokers for ADHD and 
its treatment, and the 
strategies used by the 
pharmaceutical industry to 
frame educators’ responses 
to ADHD. 
 The Teacher’s Role in 
Managing ADHD
 In his essay on 
medicalisation processes, 
Conrad argued that when 
disorders previously 
viewed as non-medical 
are redeﬁ ned as 
sicknesses, non-medical 
people often perform 
the “everyday routine 
work” of disseminating 
understanding of the 
new sickness [7]. A 
temperance society worker, 
for example, might have 
disseminated the concept 
of alcoholism as a disease 
through everyday contacts 
with alcoholics and their 
families. With ADHD, the 
teacher’s work extends 
beyond simply ensuring 
the disorder is understood 
by parents. Instead, the 
teacher participates in the diagnosis, 
and may broker different forms of 
treatment, or rejection of treatment. 
Brokerage is not a disinterested activity: 
teachers may have a vested interest in 
detecting and managing disruptive 
children, or they may adhere to beliefs 
about learning disorders which lead 
them to dissuade parents of the need 
for treatment. 
 The role of the teacher as the 
sickness and treatment broker for 
ADHD has been elaborated more 
clearly for ADHD than for any other 
childhood disorder. The DSM-IV 
diagnostic criteria accord teachers 
a formal role in diagnosis through 
specialised assessment instruments such 
as the Conners Teacher’s Rating Scale 
[8]. Teachers often agree to administer 
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psychostimulant medication during 
the school day, although there is in 
Australia, the UK, and the US no legal 
compulsion to do so. A subtle incentive 
for teachers to administer medication 
in the middle of the day may be the 
assurance of a tractable child in the 
afternoon. 
 An informal role also exists for 
teachers as “disease-spotters.” There 
appears to be considerable difference 
internationally in the alacrity with which 
teachers engage in disease-spotting. In a 
study of 491 physicians in Washington, 
D. C., almost half of the diagnoses 
of ADHD in their patients had been 
suggested ﬁ rst by teachers [9]. In 
the UK, on the other hand, parental 
concerns that a child has ADHD may be 
discounted by teachers [10]. 
 How Drug Companies Inﬂ uence 
Teachers
 As teachers have some agency 
in diagnosing ADHD, and may 
in fact contest the diagnosis, the 
pharmaceutical industry has an interest 
in directing teachers toward medical 
treatment. Pharmaceutical companies 
have been able to exploit the Internet 
to access teachers and to inﬂ uence 
their brokerage role. The approach 
to teachers tends to mirror strategies 
used to familiarise doctors with 
pharmaceuticals. 
 The pharmaceutical company as 
disinterested purveyor of education. 
The drug promotion that masquerades 
as professional education is such a 
ﬁ xture in the medical domain that 
many universities train medical 
students to critique promotional 
material. Both Shire (manufacturer 
of Adderell) [11] and Novartis 
(manufacturer of Ritalin) [12] have 
established educational websites 
separate from their own industry 
sites, each of which contains speciﬁ c 
resources for teachers. On a page 
entitled “If parents ask…,” Novartis 
suggests responses teachers might make 
to concerned parents: 
 “Make it clear to them that it is 
important for them—and their child—
to understand and follow the doctor’s 
medical advice about medication and 
other therapies for ADHD. ADHD is a 
serious condition that may require the 
child to be on medication and undergo 
counselling for a long duration [12].”
 Each site incorporates links to the 
manufacturer responsible for the site 
[13] or directly to the psychostimulant 
produced by the manufacturer [14], 
discussion of the diagnostic process, 
and references to the legislation 
governing the rights of access for 
disabled people to treatment, such 
as the Individuals with Disabilities 
Education Act in the US. An activity 
such as Shire’s funding of an annual 
toll-free “ask the experts” ADHD 
hotline, 1-888-ASK-ADHD, [15] is 
another example of the provision of 
advertorial information to teachers 
in the guise of objective education. 
Experts provided for this free hotline, 
now in its seventh year, include 
teachers, as well as school nurses, 
doctors, and advocates; suggested 
topics include the management of 
ADHD within the school. 
 Other school personnel are also 
targeted. In 1997, Novartis collaborated 
with the National Association of 
School Nurses in the US to run a 
nationwide campaign, in which 11,000 
school nurses were provided with a 
resource kit containing information 
on ADHD, its treatment, and various 
support organisations [16]. Novartis 
later collaborated with the National 
Association of School Nurses and 
others to produce a resource aimed 
at curbing misuse of psychostimulant 
medication, which again provided links 
to Novartis pharmaceuticals [17]. 
 Support of advocacy groups 
which lobby teachers. In the US, 
the pre-eminent advocacy group 
for people with ADHD is CHADD 
(Children and Adults with Attention 
Deﬁ cit/Hyperactivity Disorder). 
In the 2004–2005 ﬁ nancial year 
(year ended 30 June 2005), 22% of 
CHADD’s total revenue came from the 
pharmaceutical industry [16]. CHADD 
undertakes educational programs 
for teachers [18], including acting 
as the lead editorial consultant of a 
special issue on ADHD in Health in 
Action, a quarterly publication of the 
American School Health Association 
[19]. The UK’s answer to CHADD, the 
National Attention Deﬁ cit Disorder 
Information and Support Service 
(ADDISS), also carries a brief to 
develop and publicise educational 
programs for teachers. A charity-based 
organisation set up by the Department 
of Health, the service has also received 
funding from Janssen-Cilag, UCB 
Pharma, and Eli Lilley, according to 
reports in the UK press [20]. 
 Creating a presence in the school 
for the pharmaceutical industry. 
A more general staking of claim 
to a role in schools is provided 
through the range of online science 
educational materials now provided 
by GlaxoSmithKline [21], Pﬁ zer 
[22], and the Association of the 
British Pharmaceutical Industry [23]. 
Although these sites do not mention 
speciﬁ c medications, they reinforce the 
place of the pharmaceutical industry 
as a benevolent and authoritative 
presence within the school, much as 
the provision of branded educational 
materials to doctors reinforces the 
position of the pharmaceutical industry 
within the clinic.
 Conclusion
 The organised penetration of the 
pharmaceutical industry associated 
with ADHD into the education domain 
is a new phenomenon. While there 
has been extensive discussion about 
the ethics of fast-food marketing 
within schools [24,25], there has been 
little about the consequences of the 
pharmaceutical industry’s inﬁ ltration 
of schools. 
 It could be argued that in 
providing information to teachers, 
pharmaceutical industries are simply 
acting as good corporate citizens. 
Such an argument would carry 
more weight if these companies 
also provided education programs 
addressing autism and dyslexia, two 
other conditions which impact upon 
educational performance, but which 
 Box 1. Suggestions to Support 
Teachers as Independent 
Advocates for Children with 
ADHD
 • Teachers should be trained to decode 
and question marketing strategies 
used by the pharmaceutical industry, 
just as medical students are. 
 • Teachers should have a mechanism 
to report their observations about 
medication to an independent body, 
such as Australia’s Adverse Drugs 
Reaction Advisory Committee.
 • Teachers should contribute to 
documenting educational and other 
outcomes of children with ADHD, 
through participating in formal 
collation of data across school regions 
about outcomes.  
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do not have accepted pharmaceutical 
therapies. While there is an argument 
for providing unbiased education to 
teachers about a high-proﬁ le condition, 
education provided by pharmaceutical 
companies is self-serving in that it often 
provides education which references 
their own products, and channels the 
reader toward medical therapy. 
 There are calls for doctors to learn 
about pharmaceutical marketing 
strategies in their training [26,27], 
to participate in the monitoring of 
outcomes of medication, through post-
marketing surveillance, and to maintain 
a global watch on pharmaceutical 
marketing [28]. The wide acceptance 
of disorders of educational 
performance, and the penetration 
of the pharmaceutical industry into 
schools, point to similar needs for 
teacher training and participation in 
surveillance (see Box 1). Children 
have no agency in this market. To 
be effective advocates for children, 
teachers need to be supported to be 
objective and accurate interpreters 
of information for parents and 
healthworkers, rather than franchisees 
in the sickness marketplace.  
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